Endoscopy 2016; 48(11): 995-1002
DOI: 10.1055/s-0042-112571
Original article
© Georg Thieme Verlag KG Stuttgart · New York

Incidence of advanced neoplasia during surveillance in high- and intermediate-risk groups of the European colorectal cancer screening guidelines

Joaquín Cubiella
1   Department of Gastroenterology, Complexo Hospitalario Universitario de Ourense, Instituto de Investigación Biomédica Ourense, Pontevedra and Vigo, Ourense, Spain
,
Fernando Carballo
2   Unidad de Gestión Clínica de Digestivo, IMIB Arrixaca, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain
,
Isabel Portillo
3   Colorectal Cancer Screening Programme Coordinating Centre, Basque Health Service, Bizkaia, Spain
,
José Cruzado Quevedo
4   Programa de Cribado de Cáncer Colorrectal de la Región de Murcia, IMIB Arrixaca, Servicio Murciano de Salud, Murcia, Spain
,
Dolores Salas
5   Programa Poblacional de Cribado de Cáncer Colorrectal, Dirección General de Salud Pública, Conselleria de Sanitat, Valencia, Spain
,
Gemma Binefa
6   Programa de Prevención y Control del Cáncer, Instituto Catalán de Oncología-IDIBELL, L’Hospitalet de Llobregat, Spain
,
Núria Milà
6   Programa de Prevención y Control del Cáncer, Instituto Catalán de Oncología-IDIBELL, L’Hospitalet de Llobregat, Spain
,
Cristina Hernández
7   Servicio de Epidemiología y Evaluación, Parc de Salut Mar, IMIM, Barcelona, Spain
,
Montse Andreu
8   Servicio de Gastroenterología, Parc de Salut Mar, IMIM, Barcelona, Spain
,
Álvaro Terán
9   Servicio de Aparato Digestivo, Hospital Universitario Marqués de Valdecilla, Santander, Spain
,
Eunate Arana-Arri
10   BioCruces, Hospital Universitario Cruces, Bizkaia, Spain
,
Akiko Ono
2   Unidad de Gestión Clínica de Digestivo, IMIB Arrixaca, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain
,
María José Valverde
4   Programa de Cribado de Cáncer Colorrectal de la Región de Murcia, IMIB Arrixaca, Servicio Murciano de Salud, Murcia, Spain
,
Luis Bujanda
11   Servicio de Gastroenterología, Hospital Donostia/Instituto Biodonostia, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Universidad del País Vasco (UPV/EHU), San Sebastián, Spain
,
Vicent Hernández
12   Department of Gastroenterology, Complexo Hospitalario Universitario de Vigo, Instituto de Investigación Biomédica Ourense, Pontevedra and Vigo, Vigo, Spain
,
Juan Diego Morillas
13   Servicio de Gastroenterología, Hospital Clínico Universitario San Carlos, Madrid, Spain
,
Rodrigo Jover
14   Unidad de Gastroenterología, Hospital General Universitario de Alicante, Instituto de Investigación Biomédica ISABIAL, Alicante, Spain
,
Antoni Castells
15   Servicio de Gastroenterología, Hospital Clínic, IDIBAPS, CIBERehd, Universitat de Barcelona, Barcelona, Spain
› Author Affiliations
Further Information

Publication History

submitted: 02 November 2015

accepted after revision: 23 June 2016

Publication Date:
02 August 2016 (online)

Background and study aims: The European guidelines for quality assurance in colorectal cancer (CRC) screening have established high-risk (≥ 5 adenomas or an adenoma ≥ 20 mm) and intermediate-risk (3 – 4 adenomas or at least one adenoma 10 – 19 mm in size, or villous histology, or high grade dysplasia) groups with different endoscopic surveillance intervals. The aim of this study was to evaluate the difference in the incidence of advanced neoplasia (advanced adenoma or CRC) between the two risk groups.

Patients and methods: This retrospective group study included patients meeting high- or intermediate-risk criteria for adenomas detected in CRC screening programs and the COLONPREV study before European guidelines were adopted in Spain (June 2011) with a 3-year surveillance recommendation according to Spanish guidelines. The primary outcome measure was the incidence of advanced neoplasia in patients undergoing surveillance. The secondary outcome measure was the CRC incidence. We used an adjusted proportional hazards regression model to control confounding variables.

Results: The study included 5401 patients (3379 intermediate risk, 2022 high risk). Endoscopic surveillance was performed in 65.5 % of the patients (2.8 ± 1 years). The incidence of advanced neoplasia in the high- and intermediate-risk groups was 16.0 % (59.0 cases/1000 patient-years) and 12.3 % (41.2 cases/1000 patient-years), respectively. The CRC incidence was 0.5 % (1.4 cases/1000 patient-years) and 0.4 % (1 case/1000 patient-years), respectively. The advanced neoplasia and CRC attributable risk to the high risk group was of 3.7 % and 0.1 %, respectively. In the proportional hazards analysis, the risk of advanced neoplasia was greater in the high-risk group (hazard ratio [HR] 1.5, 95 % confidence interval [CI] 1.2 – 1.8), with no significant differences in the CRC incidence (HR 1.6, 95 %CI 0.6 – 3.8).

Conclusions: Patients meeting high-risk criteria have a higher incidence of advanced neoplasia during endoscopic surveillance. No differences were found in the CRC incidence at a 3-year surveillance recommendation.